Systems diagnostics: The systems approach to molecular imaging

American Journal of Roentgenology

Volumn 193, Issue 2, 2009, Pages 287-294

  Lee, Daniel Y ^a   Li, King C P ^a,b  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Bioinformatics; Computational biology; Genomics; Molecular imaging; Systems biology

Indexed keywords

3' FLUOROTHYMIDINE F 18; CARBON 11; DOXORUBICIN; FLUORINE 18; FLUORODEOXYGLUCOSE; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; GADOLINIUM PENTETATE MEGLUMINE; GEFITINIB; MESSENGER RNA; RADIOPHARMACEUTICAL AGENT; RUBIDIUM 82; VASCULAR CELL ADHESION MOLECULE 1;

BIOINFORMATICS; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DNA MICROARRAY; DRUG UPTAKE; FATTY ACID SYNTHESIS; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; GLIOBLASTOMA; GLUCOSE METABOLISM; HUMAN; LASER CAPTURE MICRODISSECTION; LIVER CELL CARCINOMA; MOLECULAR IMAGING; NEOPLASM; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; RNA EXTRACTION; RNA INTERFERENCE; SQUAMOUS CELL CARCINOMA; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; SYSTEMS BIOLOGY; TIME OF FLIGHT MASS SPECTROMETRY; TREATMENT RESPONSE;

COMPUTATIONAL BIOLOGY; DIAGNOSTIC TECHNIQUES AND PROCEDURES; HUMAN GENOME PROJECT; HUMANS; KNOWLEDGE BASES; MOLECULAR PROBE TECHNIQUES; MOLECULAR SEQUENCE DATA; SYSTEMS BIOLOGY;

EID: 68149163245     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.09.2866     Document Type: Review

References (71)

1. Jaffer FA, Weissleder R. Molecular imaging in the clinical arena. JAMA 2005; 293:855-862
2. Thakur M, Lentle BC. Report of a summit on molecular imaging. AJR 2006; 186:297-299
3. Hoffman JM, Gambhir SS. Molecular imaging: the vision and opportunity for radiology in the future. Radiology 2007; 244:39-47 (Pubitemid 46981957)
4. Massoud TF, Gambhir SS. Integrating noninvasive molecular imaging into molecular medicine: an evolving paradigm. Trends Mol Med 2007; 13:183-191
5. Weston AD, Hood L. Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine. J Proteome Res 2004; 3:179-196 (Pubitemid 38500984)
6. Kitano H. Systems biology: a brief overview. Science 2002; 295:1662-1664
7. Kitano H. Computational systems biology. Nature 2002; 420:206-210
8. Hood L, Heath JR, Phelps ME, Lin B. Systems biology and new technologies enable predictive and preventative medicine. Science 2004; 306:640-643 (Pubitemid 39440903)
9. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001; 42[suppl]:1S-93S (Pubitemid 32423895)
10. Czernin J, Schelbert HR. PET/CT in cancer patient management: introduction. J Nucl Med 2007; 48[suppl 1]:2S-3S
11. Czernin J, Allen-Auerbach M, Schelbert HR. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med 2007; 48[suppl 1]:78S-88S (Pubitemid 47604945)
12. Czernin J, Weber WA, Herschman HR. Molecular imaging in the development of cancer therapeutics. Annu Rev Med 2006; 57:99-118 (Pubitemid 43261981)
13. Butte AJ. Translational bioinformatics: coming of age. J Am Med Inform Assoc 2008; 15:709-714
14. Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell 2009; 136:642-655
15. Hannon GJ, Rossi JJ. Unlocking the potential of the human genome with RNA interference. Nature 2004; 431:371-378 (Pubitemid 39265678)
16. Moreno C, Lazar J, Jacob HJ, Kwitek AE. Comparative genomics for detecting human disease genes. Adv Genet 2008; 60:655-697
17. Bradley PH, Brauer MJ, Rabinowitz JD, Troyanskaya OG. Coordinated concentration changes of transcripts and metabolites in Saccharomyces cerevisiae. PLoS Comput Biol 2009; 5:e1000270
18. Koonin EV. Darwinian evolution in the light of genomics. Nucleic Acids Res 2009; 37:1011-1034
19. Koonin EV. Towards a postmodern synthesis of evolutionary biology. Cell Cycle 2009; 8:799-800
20. Guan Y, Myers CL, Lu R, Lemischka IR, Bult CJ, Troyanskaya OG. A genomewide functional network for the laboratory mouse. PLoS Comput Biol 2008; 4:e1000165
21. Yaragatti M, Sandler T, Ungar L. A predictive model for identifying mini-regulatory modules in the mouse genome. Bioinformatics 2009; 25:353-357
22. Musser JM, DeLeo FR. Toward a genome-wide systems biology analysis of host-pathogen interactions in group A Streptococcus. Am J Pathol 2005;167:1461-1472
23. Sumby P, Whitney AR, Graviss EA, DeLeo FR, Musser JM. Genome-wide analysis of group A streptococci reveals a mutation that modulates global phenotype and disease specificity. PLoS Pathog 2006; 2:e5
24. Voyich JM, Sturdevant DE, Braughton KR, et al. Genome-wide protective response used by group A Streptococcus to evade destruction by human polymorphonuclear leukocytes. PNAS 2003; 100:1996-2001
25. Sauer U, Heinemann M, Zamboni N. Genetics: getting closer to the whole picture. Science 2007; 316:550-551 (Pubitemid 46683128)
26. Silverman DH, Hoh CK, Seltzer MA, et al. Evaluating tumor biology and oncological disease with positron-emission tomography. Semin Radiat Oncol 1998; 8:183-196
27. Weber WA. Positron emission tomography as an imaging biomarker. J Clin Oncol 2006; 24:3282-3292 (Pubitemid 46622068)
28. 18F-FDG. J Nucl Med 2005; 46:945-952
29. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas. J Nucl Med 2009; 50:513-519
30. Costouros NG, Lorang D, Zhang Y, et al. Microarray gene expression analysis of murine tumor heterogeneity defined by dynamic contrast-enhanced MRI. Mol Imaging 2002; 1:301-308
31. Guccione S, Yang YS, Shi G, Lee DY, Li KC, Bednarski MD. Functional genomics guided with MR imaging: mouse tumor model study. Radiology 2003; 228:560-568 (Pubitemid 36910103)
32. Yang YS, Guccione S, Bednarski MD. Comparing genomic and histologic correlations to radiographic changes in tumors: a murine SCC VII model study. Acad Radiol 2003; 10:1165-1175 (Pubitemid 37266308)
33. Hobbs SK, Shi G, Homer R, Harsh G, Atlas SW, Bednarski MD. Magnetic resonance image-guided proteomics of human glioblastoma multiforme. J Magn Reson Imaging 2003; 18:530-536 (Pubitemid 37339797)
34. 18F-fluorodeoxyglucose uptake pattern on positron emission tomography. Eur J Nucl Med Mol Imaging 2004; 31:1621-1630
35. Wu TC. The role of vascular cell adhesion molecule-1 in tumor immune evasion. Cancer Res 2007; 67:6003-6006 (Pubitemid 47037476)
36. Kuo MD, Gollub J, Sirlin CB, Ooi C, Chen X. Radiogenomic analysis to identify imaging phenotypes associated with drug response gene expression programs in hepatocellular carcinoma. J Vasc Interv Radiol 2007; 18:821-831 (Pubitemid 46963625)
37. Segal E, Sirlin CB, Ooi C, et al. Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotechnol 2007; 25:675-680 (Pubitemid 46897204)
38. Diehn M, Nardini C, Wang DS, et al. Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. PNAS 2008; 105:5213-5218
39. Gyorffy B, Surowiak P, Kiesslich O, et al. Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer 2006; 118:1699-1712 (Pubitemid 43376433)
40. Chen X, Cheung ST, So S, et al. Gene expression patterns in human liver cancers. Mol Biol Cell 2002;13:1929-1939 (Pubitemid 34651483)
41. Gyorffy B, Serra V, Jurchott K, et al. Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival. Oncogene 2005; 24:7542-7551 (Pubitemid 41638029)
42. Segal E, Shapira M, Regev A, et al. Module networks: identifying regulatory modules and their condition-specific regulators from gene expression data. Nat Genet 2003; 34:166-176 (Pubitemid 36666927)
43. Cancela L, Hsieh CL, Francke U, Price PA. Molecular structure, chromosome assignment, and promoter organization of the human matrix Gla protein gene. J Biol Chem 1990; 265:15040-15048 (Pubitemid 20296203)
44. Luo G, Ducy P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997; 386:78-81 (Pubitemid 27130923)
45. Chen L, O'Bryan JP, Smith HS, Liu E. Overexpression of matrix Gla protein mRNA in malignant human breast cells: isolation by differential cDNA hybridization. Oncogene 1990; 5:1391-1395 (Pubitemid 20294625)
46. Beck B, Bryant S, Cheng K, et al. Molecular Imaging and Contrast Agent Database (MICAD): progress and accomplishments. J Nucl Med 2007; 48[suppl 2]:219
47. Manning HC, Lander A, McKinley E, Mutic NJ. Accelerating the development of novel molecular imaging probes: a role for high-throughput screening. J Nucl Med 2008;49:1401-1404
48. Wester HJ. Nuclear imaging probes: from bench to bedside. Clin Cancer Res 2007; 13:3470-3481 (Pubitemid 46955106)
49. Su H, Seimbille Y, Ferl GZ, et al. Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. Eur J Nucl Med Mol Imaging 2008; 35:1089-1099
50. Schreiber SL. Target-oriented and diversity-oriented organic synthesis in drug discovery. Science 2000; 287:1964-1969
51. Jacobson-Kram D, Mills G. Leveraging exploratory investigational new drug studies to accelerate drug development. Clin Cancer Res 2008; 14:3670-3674
52. Murgo AJ, Kummar S, Rubinstein L, et al. Designing phase 0 cancer clinical trials. Clin Cancer Res 2008; 14:3675
53. Doroshow JH, Parchment RE. Oncologic phase 0 trials incorporating clinical pharmacodynamics: from concept to patient. Clin Cancer Res 2008; 14:3658
54. Hargreaves RJ. The role of molecular imaging in drug discovery and development. Clin Pharmacol Ther 2008; 83:349-353
55. Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS. Molecular imaging in drug development. Nat Rev Drug Discov 2008; 7:591-607
56. 18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res 2006; 12:3942-3949
57. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature 2004; 429:464-468 (Pubitemid 38715141)
58. Ballatori N, Villalobos AR. Defining the molecular and cellular basis of toxicity using comparative models. Toxicol Appl Pharmacol 2002; 183:207-220 (Pubitemid 35173921)
59. Davis AP, Murphy CG, Saraceni-Richards CA, Rosenstein MC, Wiegers TC, Mattingly CJ. Comparative toxicogenomics database: a knowledge-base and discovery tool for chemical-gene-disease networks. Nucleic Acids Res 2009; 37[database issue]:D786-D792
60. di Bernardo D, Thompson MJ, Gardner TS, et al. Chemogenomic profiling on a genome-wide scale using reverse-engineered gene networks. Nat Biotechnol 2005; 23:377-383 (Pubitemid 41094431)
61. Duarte NC, Becker SA, Jamshidi N, et al. Global reconstruction of the human metabolic network based on genomic and bibliomic data. PNAS 2007; 104:1777-1782 (Pubitemid 46239855)
62. 18F-FDG. J Nucl Med 2008; 49:186-194
63. Ho CL, Chen S, Yeung DW, Cheng TK. Dualtracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma. J Nucl Med 2007; 48:902-909 (Pubitemid 46909918)
64. 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med 2008; 49:1912-1921
65. 18F-FDG. J Nucl Med 2003; 44:1426-1431
66. 18F-fluorodeoxyglucose-positron emission tomography. Chest 2006; 129:393-401
67. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 2001; 291:1304-1351
68. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 2001; 409:860-921 (Pubitemid 32165345)
69. Ivanova NB, Dimos JT, Schaniel C, Hackney JA, Moore KA, Lemischka IR. A stem cell molecular signature. Science 2002; 298:601-604
70. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007; 8:286-298 (Pubitemid 46439286)
71. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128:683-692